Opinion|Videos|August 7, 2024

Patient Selection and Switching Patients to Subcutaneous Infliximab

Jean-Frederic Colombel, MD, examines considerations for transitioning patients from intravenous to subcutaneous infliximab and evaluates the role of subcutaneous infliximab within the evolving landscape of inflammatory bowel disease treatments.

  1. For patients currently receiving IV infliximab (originator or biosimilar), are there any considerations for switching them to subcutaneous infliximab?
  2. How will subcutaneous infliximab fit in with the growing IBD treatment landscape?

Latest CME